No Data
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Latest 23% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Ginkgo Bioworks: Underperform Rating Due to Financial Strain and Uncertain Strategic Outcomes
Express News | Ginkgo Bioworks Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Revenue Results
Express News | Ginkgo Bioworks Holdings Qtrly Shr Loss $0.11
Express News | Ginkgo Bioworks Holdings Inc: Reaffirms Total Revenue of $170-$190 Mln in 2024
Express News | Ginkgo Bioworks : Provides Update on Its Restructuring Process Including Estimated Annualized Cost Savings of Over $85 Mln From Reduction in Force
Edozz OP : maybe. its back at my origional buy in now.